General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Alnylam(MODEST), Novo Nordisk Inc.(MODEST), Arbor Biotechnologies(SIGNIFICANT), Attralus(MODEST), Prothena(MODEST), Bristol-Myers Squibb Company (MODEST) RESEARCH/RESEARCH GRANTS: Bridgebio(NONE)

View Full Disclosure